Our results underscore the significant impact of targeted therapies, such as EGFR-TKIs, on improving overall survival in patients with EGFR mutation-positive NSCLC, highlighting the importance of molecular diagnostics in guiding treatment decisions. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.